<DOC>
	<DOCNO>NCT01031758</DOCNO>
	<brief_summary>The purpose study investigate use radiolabeled particulate cholesterol administer intravenously association albumin , method study reverse cholesterol transport ( RCT ) humans analyze change tracer activity total plasma , lipoproteins feces .</brief_summary>
	<brief_title>Reverse Cholesterol Transport ( RCT ) Study</brief_title>
	<detailed_description>The study use 3H-cholesterol bound albumin ( particulate cholesterol ) ass ability HDL transport cholesterol liver eliminate . This process call Reverse Cholesterol transport one main mechanism HDL protect atherosclerotic cardiovascular disease . The availability method ass RCT important development new drug affect RCT may result useful treatment atherosclerosis . This study evaluate use radiolabeled particulate cholesterol administer intravenously association albumin , method study reverse cholesterol transport ( RCT ) humans analyze change tracer activity total plasma lipoprotein . The study population healthy volunteer .</detailed_description>
	<criteria>Group 1 ( 6 subject ) : 1 . Men woman age 18 70 2 . HDL cholesterol ( HDLC ) define level ≥ 25th percentile ≤ 75th percentile age , gender race 3 . Female subject must nonchildbearing potential . They must surgically sterilize least 6 month prior screen postmenopausal . Postmenopausal woman must regular menstrual bleeding least 2 year prior inclusion . 4 . Subjects must good overall health 5 . Subjects must able comprehend willing provide sign IRB approve Informed Consent Form . 6 . Subjects must willing comply studyrelated procedure . Group 2 ( 6 subject ) : 1 . Men woman age 18 70 2 . HDL cholesterol ( HDLC ) define level &lt; 25th percentile age , gender race 3 . Female subject must nonchildbearing potential . They must surgically sterilize least 6 month prior screen postmenopausal . Postmenopausal woman must regular menstrual bleeding least 2 year prior inclusion . 4 . Subjects must good overall health 5 . Subjects must able comprehend willing provide sign IRB approve Informed Consent Form . 6 . Subjects must willing comply studyrelated procedure . Group 3 ( 6 subject ) : 1 . Men woman age 18 70 2 . HDL cholesterol ( HDLC ) define level &gt; 75th percentile age , gender race 3 . Female subject must nonchildbearing potential . They must surgically sterilize least 6 month prior screen postmenopausal . Postmenopausal woman must regular menstrual bleeding least 2 year prior inclusion . 4 . Subjects must good overall health 5 . Subjects must able comprehend willing provide sign IRB approve Informed Consent Form . 6 . Subjects must willing comply studyrelated procedure . 1 . Known cardiovascular disease , include coronary disease , cerebrovascular disease , peripheral vascular disease 2 . History diabetes mellitus fast glucose &gt; 126 mg/dL screen visit . 3 . History endocrine disease 4 . History nonskin malignancy within previous 5 year 5 . Anemia ; Hemoglobin le 10 g/dL 6 . Renal insufficiency define creatinine ³ 1.3 mg/dl 7 . Any major active rheumatologic , pulmonary , dermatologic disease inflammatory condition 8 . History hypertension 9 . Use warfarin , know coagulopathy /or elevate PT/PTT &gt; 1.5 x ULN 10 . Selfreported history HIV positive 11 . Previous organ transplantation 12 . Clinical evidence liver disease liver injury indicate abnormal liver function test ALT AST &gt; 1x ULN , selfreported history positive Hepatitis B Hepatitis C test result 13 . Any major surgical procedure occur within previous 3 month screen visit 14 . Use tobacco product currently previous 30 day 15 . History drug abuse ( &lt; 3 year ) 16 . Regular use alcoholic beverage ( &gt; 2 drinks/day ) 17 . Body mass index ( BMI ) &gt; 30 kg/m2 &lt; 18.5 kg/m2 18 . Participation investigational drug study within 6 week prior screen visit 19 . Serious unstable medical psychological condition , opinion investigator , would compromise subject 's safety successful participation study exclude . 20 . Use lipid lower drug within 6 week prior dose study 21 . Use prescription nonprescription drug ( include vitamin herbal supplement , exclude replacement hormone therapy ) within 2 week prior dose study , however , acetaminophen 2g/day acceptable . 22 . Male subject plan conceive child within 3 month conclusion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Low HDL</keyword>
	<keyword>High HDL</keyword>
	<keyword>HDL</keyword>
	<keyword>Reverse Cholesterol Transport</keyword>
	<keyword>RCT</keyword>
	<keyword>healthy volunteer</keyword>
	<keyword>3H</keyword>
	<keyword>Average HDL</keyword>
</DOC>